ADMA Biologics receives FDA approval for yield enhancement process; expects ~20% output increase

ADMA BIOLOGICS, INC.

FDA approved innovative production yield enhancement process increasing yields by ~20% from same plasma volume.
Approval applies to both immune globulin products ASCENIV and BIVIGAM.
CEO anticipates revenue and earnings acceleration beginning late 2025 and accelerating into 2026.
First U.S. regulatory approval for such a process; highlights ADMA's internal R&D and capital efficiency.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.